Date Published 
July 2013

Page Count
105

Additional Info 
Single-site, country, and global licenses are multi-user, searchable, and cut-and-paste ready PDFs delivered by e-mail.

 

For Corporate Subscriptions, Multi-Reports Orders, Discounts or Order Questions.  

Contact:
Kerri Kelley
Customer Service
781-972-1347 


IPR Bundle

Molecular Biomarkers for Cancer Detection and Management: Table of Contents

Executive Summary

  • Background and history
  • Basic research
  • Commercial applications
  • Market dynamics
  • Survey results
  • Trends and conclusions

CHAPTER 1: Introduction

  • Scope and contents

CHAPTER 2: Background and History

  • First-generation cancer biomarkers
  • Categorization of cancer biomarkers
    • Disease detection biomarkers
    • Prognostic biomarkers
    • Companion diagnostic biomarkers
  • Omic era cancer biomarkers
  • Failed efforts and stumbling blocks

CHAPTER 3: Basic Research

  • Screening, detection, risk, and monitoring
    • Screening
  • Prognosis and prediction
  • Companion Diagnostics
  • Metastasis
    • Circulating tumor cells
    • Exosomes
  • MicroRNA (miRNA)

CHAPTER 4: Commercial Applications

  • Screening, detection, risk assessment, and monitoring biomarkers
    • Alere
    • Allegro Diagnostics
    • Atossa Genetics
    • Biophysical Corporation
    • Exact Sciences
    • Exosome Diagnostics
    • Matrix-Bio
    • MDx Health
    • Mitomics
    • Myriad Genetics
    • Oncimmune
    • Onconome
    • Predictive Biosciences
    • Sphingotec
  • Prognosis and prediction biomarkers
    • Agendia
    • Abbott Molecular
    • Atossa Genetics
    • Biocept
    • bioTheranostics
    • DiagnoCure
    • GenomeDx Biosciences
    • Genomic Health
    • Gen-Probe
    • Life Technologies
    • MetaStat
    • Predictive Biosciences
    • Skyline Diagnostics
    • Trovagene
    • Veridex
  • Companion diagnostic biomarkers
    • 20/20 GeneSystems
    • Abbott Molecular
    • Cynvenio
    • Dako (Agilent)
    • Epic Sciences
    • Foundation Medicine
    • Genomic Health
    • Molecular Response Corp.
    • Nodality
    • Personal Genome Diagnostics
      • Interview with founder, Luis Diaz, MD
    • Qiagen
    • Roche Molecular Systems

CHAPTER 5: Market Dynamics

  • Competitive Environment
  • Sales Estimates and Projections
  • Mergers and acquisitions
  • Cancer detection, risk, and prognostic assay deals
    • Liquid Biopsy AB and Roche
    • Oxford Gene Technology
    • Abbott and Stanford University
    • Ipsogen and Personal Genome Diagnostics (PDGx)
  • Companion diagnostic assay deals
    • Abbott and Merck
    • Affymetrix and Massachusetts General Hospital (MGH)
    • Agilent/Dako and Genentech
    • Eli Lilly
    • Foundation Medicine
    • GE Healthcare and Insight Genetics
    • Genomic Health and OncoMed Pharmaceuticals
    • HTG Molecular Diagnostics and Merck
    • Life Technologies and Others
    • Qiagen and Boehringer Ingelheim
    • Quintiles and Oxford Cancer Biomarkers
    • Roche/Ventana and other companies
    • Verastem and Labcorp
  • Survey Results

CHAPTER 6: Observations and Conclusions

  • Companion diagnostics
  • Circulating tumor cells and nucleic acids
  • EMT biomarkers
  • Tumor Heterogeneity
  • Costs and reimbursement

CHAPTER 7: Interview Transcripts

  • Luis Diaz, MD, Associate Professor of Oncology, Johns Hopkins School of Medicine; Chief Medical Officer and Founder Personal Genome Diagnostics
  • Jorge Nieva, MD, Oncologist and Hematologist,Billings Clinic,Billings Montana
  • Harry Glorikian, Managing Partner and Founder, Scientia Advisors
  • Paul Dempsey, Ph.D., Chief Science Officer, CynvenioBiosystems
  • Scott Kern, M.D., Professor of Oncology and Pathology, Sidney Kimmel Comprehensive Cancer Center, Johns Hopkins University School of Medicine
  • About Cambridge Healthtech Institute